A Safety Study of LY3462817 in Healthy Participants

Summary

This study is being conducted to determine how safe and how well tolerated LY3462817 is when given intravenously (IV) (into a vein) and subcutaneously (SC) (just under the skin) to healthy participants. Blood tests will be done to check how much LY3462817 is in the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive 1 dose of LY3462817 or placebo. The study will last about 16 weeks, including screening.

Timeline

Start

2018-12-13

Primary completion

2019-12-11

Completion

2019-12-11

Drugs

Indications

No indication recorded.